The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model

British Journal of Pharmacology

Volumn 147, Issue 8, 2006, Pages 873-885

  Martín, Antonio Ramón ^a   Villegas, Isabel ^a   Sánchez Hidalgo, Marina ^a   De La Lastra, Catalina Alarcón ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Apoptosis; Cyclooxygenase (COX); Neutrophils; Nuclear transcription factor NF kappa B (NF B); Prostaglandin (PG); Resveratrol; Trinitrobenzenesulphonic acid (TNBS)

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; NATURAL PRODUCT; P65 IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHYTOALEXIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; RESVERATROL; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC INFLAMMATION; COLITIS; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME ACTIVITY; GRAPE; HISTOPATHOLOGY; ICOSANOID METABOLISM; IMMUNOMODULATION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RED WINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; COLON; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; MEMBRANE PROTEINS; NF-KAPPA B; PEROXIDASE; PROSTAGLANDIN D2; RATS; RATS, WISTAR; SESQUITERPENES; STILBENES; TERPENES; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA; WINE;

EID: 33646572516     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706469     Document Type: Article

References (56)

1. AJUEBOR, M.N., SINGH, A. & WALLACE, J.L. (2000). Cyclooxygenase-2- derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol., 279, G238-G244.
2. ALARCÓN DE LA LASTRA, C. & VILLEGAS, I. (2005). Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res., 49, 405-430.
3. 2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation. Gastroenterology, 96, 1290-1300.
4. AMORATI, R., LUCARINI, M., MUGNAINI, V., PEDULLI, G.F., ROBERTI, M. & PIZZIRANI, D. (2004). Antioxidant activity of hydroxystilbene derivatives in homogeneous solution. J. Org. Chem., 69, 7101-7107.
5. AZIZ, M.H., REAGAN-SHAW, S., WU, J., LONGLEY, B.J. & AHMAD, N. (2005). Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J., 19, 1193-1195 [express article 10.1096/fj.04-3582fje. Published online April 18, 2005].
6. BAOLIN, L., INAMI, Y., TANAKA, H., INAGAKI, N., IINUMA, M. & NAGAI, H. (2004). Resveratrol inhibits the release of mediators from bone marrow-derived mouse mast cells in vitro. Planta Med., 70, 305-309.
7. BELGUENDOUZ, L., FREMONT, L. & GOZZELINO, M.T. (1998). Interaction of transresveratrol with plasma lipoproteins. Biochem. Pharmacol., 55, 811-816.
8. BERENGUER, B., ALARCÓN DE LA LASTRA, C., MORENO, F.J. & MARTIN, M.J. (2002). Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors. Eur. J. Pharmacol., 3, 125-135.
9. BERNHARD, D., SCHWAIGER, W., CRAZZOLARA, R., TINHOFER, I., KOFLER, R. & CSORDAS, A. (2003). Enhanced MTT-reducing activity under growth inhibition by resveratrol in CEM-C7H2 lymphocytic leukemia cells. Cancer Lett., 195, 193-199.
10. BI, X.L., YANG, J.Y., DONG, Y.X., WANG, J.M., CUI, Y.H., IKESHIMA, T., ZHAO, Y.Q. & WU, C.F. (2005). Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int. Immunopharmacol., 5, 185-193.
11. BOBIN-DUBIGEON, C., COLLIN, X., GRIMAUD, N., ROBERT, J.M., LE BAUT, G. & PETIT, J.Y. (2001). Effects of tumor necrosis factor-α synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis. Eur. J. Pharmacol., 42, 103-110.
12. BODE, A.M. & DONG, Z. (2004). Targeting signal transduction pathways by chemopreventive agents. Mutat. Res., 555, 33-51.
13. BOSCOLO, P., DEL SIGNORE, A., SABBIONI, E., DI GIOACCHINO, M., DI GIAMPAOLO, L., REALE, M., CONTI, P., PAGANELLI, R. & GIACCIO, M. (2003). Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann. Clin. Lab. Sci., 33, 226-231.
14. CAL, C., GARBAN, H., JAZIREHI, A., YEH, C., MIZUTANI, Y. & BONAVIDA, B. (2003). Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr. Med. Chem. Anti-Cancer Agents, 3, 77-93.
15. CHUNG, S.W., KANG, B.Y., KIM, S.H., PAK, Y.K., CHO, D., TRINCHIERI, G. & KIM, T.S. (2000). Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κ B. J. Biol. Chem., 275, 32681-32687.
16. D'ARGENIO, G., FARRACE, M.G., COSENZA, V., DE RITIS, F., DELLA VALLE, N., MANGUSO, F. & PIACENTINI, M. (2004). Expression of apoptosis-related proteins in rat with induced colitis. Int. J. Colorect. Dis., 19, 451-460.
17. DENIZ, M., CETINEL, S. & KURTEL, H. (2004). Blood flow alterations in TNBS-induced colitis: role of endothelin receptors. Inflamm. Res., 53, 329-336.
18. DIJKSTRA, G., MOSHAGE, H. & JANSEN, PL. (2002). Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scand. J. Gastroenterol., 236 (Suppl), 37-41.
19. DONG, Z. (2003). Molecular mechanism of the chemopreventive effect of resveratrol. Mutat. Res., 523-524, 145-150.
20. DUBUQUOY, L., DHARANCY, S., NUTTEN, S., PETTERSSON, S., AUWERX, J. & DESREUMAUX, P. (2002). Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet, 2, 1410-1418.
21. EINERHAND, A.W., RENES, I.B., MAKKINK, M.K., VAN DER SLUIS, M., BULLER, H.A. & DEKKER, J. (2002). Role of mucins in inflammatory bowel disease: important lessons from experimental models. Eur. J. Gastroenterol. Hepatol., 14, 757-765.
22. ESTROV, Z., SHISHODIA, S., FADERL, S., HARRIS, D., VAN, Q., KANTARJIAN, HM., TALPAZ, M. & AGGARWAL, B.B. (2003). Resveratrol blocks interleukin-1 {beta}-induced activation of the nuclear transcription factor NF-{kappa}B, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukaemia cells. Blood, 102, 987-995.
23. FEDORAK, R.N., EMPEY, L.R., MACARTHUR, C. & JEWELL, L.D. (1990). Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology, 98, 615-625.
24. GAO, X., XU, Y.X., JANAKIRAMAN, N., CHAPMAN, R.A. & GAUTAM, S.C. (2001). Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem. Pharmacol., 62, 1299-1308.
25. GILROY, D.W., COLVILLE-NASH, P.R., WILLIS, D., CHIVERS, J., PAUL-CLARK, M.J. & WILLOUGHBY, D.A. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med., 5, 698-701.
26. GRISHAM, M.B., BENIOT, J.N. & GRANGER, D.N. (1990). Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol., 186, 729-742.
27. HAN, Y.S., ZHENG, W.H., BASTIANETTO, S., CHABOT, J.G. & QUIRION, R. (2004). Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol., 141, 997-1005.
28. HAYASHIBARA, T., YAMADA, Y., NAKAYAMA, S., HARASAWA, H., TSURUDA, K., SUGAHARA, K., MIYANISHI, T., KAMIHIRA, S., TOMONAGA, M. & MAITA, T. (2002). Resveratrol induces down-regulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr. Cancer, 44, 193-201.
29. HELENIUS, M., HANNINEN, M., LEHTINEK, S.K. & SALMINEN, A. (1996). Changes associate with aging and replicative senescence in the regulation of transcription factor nuclear factor-κB. Biochem. J., 318, 603-608.
30. HOLMES-MCNARY, M. & BALDWIN, A.S.JR. (2000). Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res., 60, 3477-3483.
31. HOWITZ, K.T., BITTERMAN, K.J., COHEN, H.Y., LAMMING, D.W., LAVU, S., WOOD, J.G., ZIPKIN, R.E., CHUNG, P., KISIELEWSKI, A., ZHANG, L.L., SCHERER, B. & SINCLAIR, D.A. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425, 191-196.
32. HUNG, L.M., CHEN, J.K., HUANG, S.S., LEE, R.S. & SU, M.J. (2000). Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res., 47, 549-555.
33. KANKURI, E., VAALI, K., KORPELA, R., PAAKKARI, I., VAPAATALO, H. & MOILANEN, E. (2001). Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation, 25, 301-309.
34. KIM, S.W., CHOI, S.C., CHOI, E.Y., KIM, K.S., OH, J.M., LEE, H.J., OH, H.M., KIM, S., OH, B.S., KIMM, K.C., LEE, M.H., SEO, G.S., KIM, T.H., OH, H.C., WOO, W.H., KIM, Y.S., PAE, H.O., PARK, D.S., CHUNG, H.T. & JUN, C.D. (2004). Catalposide, a compound isolated from catalpa ovata, attenuates induction of intestinal epithelial proinflammatory gene expression and reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice. Inflamm. Bowel Dis., 10, 564-572.
35. KURTOVIC, J. & SEGAL, I. (2004). Recent advances in biological therapy for inflammatory bowel disease. Trop. Gastroenterol., 25, 9-14.
36. LAWRANCE, I.C., WU, F., LEITE, A.Z., WILLIS, J., WEST, G.A., FIOCCHI, C. & CHAKRAVARTI, S. (2003). A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology, 125, 1750-1761.
37. LIU, L., MEI, Q.B., ZHOU, S.Y., HAN, F.H., LONG, Y., LIU, J.Y., LI, C., MENG, J.R. & WANG, Z.P. (2003). Effects of tanguticum maxim polysaccharide on ulcerative colitis induced by TNBS in rats. Zhongguo Zhong Yao Za Zhi, 28, 246-249.
38. MARTÍN, A.R., VILLEGAS, I., LA CASA, C. & ALARCÓN DE LA LASTRA, C. (2003). The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur. J. Pharmacol., 481, 281-291.
39. MARTÍN, A.R., VILLEGAS, I., LA CASA, C. & ALARCÓN DE LA LASTRA, C. (2004). Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem. Pharmacol., 67, 1399-1410.
40. MARTÍNEZ, J. & MORENO, J.J. (2000). Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol., 59, 865-870.
41. MORRIS, G.P., BECK, P.L., HERRIDGE, M.S., DEPEW, W.T., SZEWCZUK, M.R. & WALLACE, J.L. (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 96, 795-803.
42. NAWADA, N., SEKI, S., INOUE, M. & KUROKI, T. (1998). Effect of antioxidants, resveratrol, quercetin, and N-acetykcysteine, on the functions of cultural rat hepatic stellate cells and Kupffer cells. Hepatology, 27, 1265-1274.
43. SANDBORN, W.J. & YEDNOCK, T.A. (2003). Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am. J. Gastroenterol., 98, 2372-2382.
44. SASAKI, M., ELROD, J.W., JORDAN, P., ITOH, M., JOH, T., MINAGAR, A. & ALEXANDER, J.S. (2004). CYP450 dietary inhibitors attenuate TNF-alpha-stimulated endothelial molecule expression and leukocyte adhesion. Am. J. Physiol. Cell Physiol., 286, C931-C939.
45. SCHMIDT, C. & STALLMACH, A. (2005). Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol. Dietol., 51, 127-145.
46. SZEWCZUK, L.M. & PENNING, T.M. (2004). Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J. Nat. Prod., 67, 1777-1782.
47. TESSNER, T.G., COHN, S.M., SCHLOEMANN, S. & STENSON, W.F. (1998). Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology, 115, 874-882.
48. THOMPSON-CHAGOYAN, O.C., MALDONADO, J. & GIL, A. (2005). Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin. Nutr., 24, 339-352.
49. TORRES, M.I., GARCÍA-MARTÍN, M., FERNÁNDEZ, M.I., NIETO, N., GIL, A. & RÍOS, A. (1999). Experimental colitis induced by trinitrobenzenesulphonic acid. An ultrastructural and histochemical study. Digest. Dis. Sci., 44, 2523-2529.
50. VILLEGAS, I., ALARCÓN DE LA LASTRA, C., ORJALES, A. & LA CASA, C. (2003a). A new flavonoid derivative, dosmalfate, attenuates the development of dextran sulphate sodium-induced colitis in mice. Int. Immunopharmacol., 3, 1731-1741.
51. VILLEGAS, I., LA CASA, C., ORJALES, A. & ALARCÓN DE LA LASTRA, C. (2003b). Effects of dosmalfate, a new cytoprotective agent, on acute and chronic trinitrobenzene sulphonic acid-induced colitis in rats. Eur. J. Pharmacol., 460, 209-218.
52. WINGREN, U. & ENERBÄCK, L. (1983). Mucosal mast cells of the rat intestine: a re-evaluation of fixation and staining properties, with special reference to protein blocking and solubility of the granular glycosaminoglycan. Histochem J., 15, 571-582.
53. YEUNG, F., HOBERG, J.E., RAMSEY, C.S., KELLER. M.D., JONES, D.R., FRYE, R.A. & MAYO, M.W. (2004). Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 23, 2369-2380.
54. YUE, G., LAI, P.S., YIN, K., SUN, F.F., NAGELE, R.G., LIU, X., LINASK, K.K., WANG, C., LIN, K.T. & WONG, P.Y. (2001). Colon epithelial cell death in 2,4,6-trinitrobenzenesulfonic acid-induced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production. J. Pharmacol. Exp. Ther., 297, 915-925.
55. ZAMUNER, S.R., WARRIER, N., BUREO, A.G., MACNAUGHTON, W.K. & WALLACE, J.L. (2003). Cyclooxygenase 2 mediates post-inflammatory colonie secretory and barrier dysfunction. Gut, 52, 1714-1720.
56. ZHOU, H.B., YAN, Y., SUN, Y.N. & ZHU, J.R. (2003). Resveratrol induces apoptosis in human esophageal carcinoma cells. World J. Gastroenterol., 9, 408-411.